NDLI: Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies

Please wait, while we are loading the content...

Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis

The P450 oxidoreductase (POR) rs2868177 and cytochrome P450 (CYP) 2B6*6 polymorphisms contribute to the interindividual variability in human CYP2B6 activity

Serotonin transporter gene (SLC6A4) polymorphisms are associated with response to fluoxetine in south Indian major depressive disorder patients

Levobupivacaine absorption pharmacokinetics with and without epinephrine during TAP block: analysis of doses based on the associated risk of local anaesthetic toxicity

Evaluating patients’ comprehensibility of a standardized medication plan

Ibuprofen-associated hypothermia in children: analysis of the Italian spontaneous reporting database

Changes in utilisation of antiepileptic drugs in epilepsy and non-epilepsy disorders—a pharmacoepidemiological study and clinical implications

Effect of prehospital epinephrine on out-of-hospital cardiac arrest: a report from the national out-of-hospital cardiac arrest data registry in Japan, 2011–2012

Use of cardioselective β-blockers and overall death and cardiovascular outcomes in patients with COPD: a population-based cohort study

Do the EMA accelerated assessment procedure and the FDA priority review ensure a therapeutic added value? 2006–2015: a cohort study

Prevention of selective outcome reporting: let us start from the beginning

European Journal of Clinical Pharmacology : Volume 72, Issue 9, September 2016

European Journal of Clinical Pharmacology : Volume 72, Issue 7, July 2016

European Journal of Clinical Pharmacology : Volume 72, Issue 6, June 2016

European Journal of Clinical Pharmacology : Volume 72, Issue 2, February 2016

European Journal of Clinical Pharmacology : Volume 67

European Journal of Clinical Pharmacology : Volume 62

European Journal of Clinical Pharmacology : Volume 57

Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies—a systematic review

Content Provider	Springer Nature Link
Author	Arnlind, Marianne Heibert Fryklund, Linda Vitols, Sigurd Bertilsson, Göran
Copyright Year	2016
Abstract	We systematically reviewed published observational studies and randomized controlled trials (RCT) reports of clinical trials on erythropoiesis-stimulating agents (ESA’s). Only studies evaluating the risk of developing anti-drug antibodies (ADA) of both original and biosimilar drugs were chosen.Databases including PubMed, EMBASE and Cochrane Library were searched up to 17 March 2015. Two reviewers independently assessed the relevant studies for risk of bias.Twenty-one publications were included. The overall prevalence of ADA in the studies was about 0.2 to 0.5 %. Most studies were not designed to monitor the development of ADA and often the study duration was too short (less than 6 months) and the patient population too small. Moreover, in many studies, the assays used only determined the presence of ADA and did not measure therapy failure due to ADA. In one RCT, as many as 13 cases (4 %) of ADA were identified.ADA development seems to be low in short-term studies with ESA. None of the efficacy and safety issues for ESA biosimilars were judged to be adequately addressed in the evaluated literature, with respect to ADA formation, due to the study design and the assay method used.
Starting Page	1161
Ending Page	1169
Page Count	9
File Format	PDF
ISSN	00316970
Journal	European Journal of Clinical Pharmacology
Volume Number	72
Issue Number	10
e-ISSN	14321041
Language	English
Publisher	Springer Berlin Heidelberg
Publisher Date	2016-07-21
Publisher Place	Berlin, Heidelberg
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Erythropoiesis-stimulating agents Biosimilar Efficacy Antibodies Systematic review Pharmacology/Toxicology
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

NSAIDs and the risk of accidental falls in the elderly: a systematic review.

Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.

Safety and tolerability profile of second-line anti-tuberculosis medications.

Erythropoiesis-stimulating agents in cancer patients: reflections on safety.

Comment on 'Drug-induced thrombocytopenia: an updated systematic review'.

Biosimilar regulation in the EU.

Colistin: efficacy and safety in different populations.

Benefit-risk assessment of diacerein in the treatment of osteoarthritis.

The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.

Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies—a systematic review

Similar Documents

NSAIDs and the risk of accidental falls in the elderly: a systematic review.

Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.

Safety and tolerability profile of second-line anti-tuberculosis medications.

Erythropoiesis-stimulating agents in cancer patients: reflections on safety.

Comment on 'Drug-induced thrombocytopenia: an updated systematic review'.

Biosimilar regulation in the EU.

Colistin: efficacy and safety in different populations.

Benefit-risk assessment of diacerein in the treatment of osteoarthritis.

The Safety of Erythropoiesis-Stimulating Agents for the Treatment of Anemia Resulting from Chronic Kidney Disease.

Biosimilar erythropoiesis-stimulating agents and the risk of developing anti-drug antibodies—a systematic review